Coloplast stock edges lower despite strong quarterly profit surge
Published on 09/15/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast stock (ISIN DK0060448595) traded at DKK 418.60 on Nasdaq Copenhagen as of September 15, 2026, slipping 0.14% from the prior close of DKK 419.20 after a period of strong reported profit growth for the Danish medical-device group.
Quarterly results show sharply higher profit
According to Ad-hoc-news on September 14, 2026, Coloplast recently reported an 82 percent jump in operating profit for its latest quarter under its new chief executive, marking one of the strongest profit increases in recent reporting periods for the company.
In the same coverage, Ad-hoc-news highlighted that the margin performance in the latest quarter was described as a surge, indicating that profitability improved markedly compared with the prior year’s corresponding period, even though the stock price reaction was muted.
Market reaction and recent price levels
Per market data published by MarketWatch, Coloplast B A/S on Nasdaq Copenhagen was last quoted at DKK 418.60 on September 15, 2026, at 12:37 p.m. CEDT, down 0.60 DKK or 0.14% from the previous close of DKK 419.20.
On September 14, 2026, exchange data cited by Ad-hoc-news showed Coloplast stock closing at DKK 419.20 on Nasdaq Copenhagen, representing a 0.75% gain on the day, while Danish large-cap peers in the OMXC Large Cap index traded mixed.
In a separate report, Ad-hoc-news noted that on another recent session Coloplast B A/S declined 1.35 percent to a last price of DKK 446.70, underperforming Danish peers such as Carlsberg B A/S and Genmab A/S, which showed positive moves on the same day.
Analyst consensus and valuation backdrop
Analyst data compiled by MarketScreener on September 15, 2026, show that the mean consensus rating on Coloplast stock is Hold, based on assessments from 21 analysts.
According to the same MarketScreener overview, the average target price stands at DKK 468.29 compared with a last close price of DKK 419.20, implying an upside of 11.71 percent relative to that reference.
Within the same analyst compilation on MarketScreener, Danske Bank is cited as having raised its target price for Coloplast to DKK 470 from DKK 450 while reiterating a Hold recommendation on August 28, 2026, and Kepler Cheuvreux is reported to have lifted its price target while maintaining a Buy rating, offering a supportive view on the stock.
Risk factors and downgrades temper optimism
The analyst landscape also contains more cautious views. As reported in the same MarketScreener consensus page, JP Morgan downgraded Coloplast to Underweight from Neutral on September 9, 2026, and put the stock, alongside Ambu and Elekta, on negative watch.
This combination of an 82 percent rise in operating profit in the latest quarter, as highlighted by Ad-hoc-news, and a consensus Hold rating with an average target price modestly above the current level, as shown by MarketScreener, suggests that investors are weighing strong near-term profitability against valuation, competitive pressures and execution risks under the new leadership.
Stock price and trading data
As of September 15, 2026, at 12:37 p.m. CEDT, Coloplast B A/S was quoted at DKK 418.60 on its primary listing, Nasdaq Copenhagen, with the previous close at DKK 419.20 and an intraday decline of 0.14%, according to price data reported by MarketWatch for the COLO.B symbol.
Coloplast stock key data
- Company: Coloplast A/S
- ISIN: DK0060448595
- Ticker: COLO.B
- Trading venue: Nasdaq Copenhagen
- Price (as of September 15, 2026, 12:37): 418.60 DKK
- Market capitalization: [value] DKK (as of September 15, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: OMXC Large Cap
